Renal Osteodystrophy (ROD), the bone component of CKD-mineral bone disorder (CKD-MBD3), is traditionally assessed using histomorphometry, with high turnover bone disease treated by reducing parathyroid hormone (PTH) with calcitriol or calcimimetics. This evidence concerns the gene PTH and renal osteodystrophy.